Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 23;11(9):2380.
doi: 10.3390/jcm11092380.

Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease

Affiliations
Review

Optimizing the Outcomes of Percutaneous Coronary Intervention in Patients with Chronic Kidney Disease

Alessandro Caracciolo et al. J Clin Med. .

Abstract

Percutaneous coronary intervention (PCI) is one of the most common procedures performed in medicine. However, its net benefit among patients with chronic kidney disease (CKD) is less well established than in the general population. The prevalence of patients suffering from both CAD and CKD is high, and is likely to increase in the coming years. Planning the adequate management of this group of patients is crucial to improve their outcome after PCI. This starts with proper preparation before the procedure, the use of all available means to reduce contrast during the procedure, and the implementation of modern strategies such as radial access and drug-eluting stents. At the end of the procedure, personalized antithrombotic therapy for the patient's specific characteristics is advisable to account for the elevated ischemic and bleeding risk of these patients.

Keywords: chronic kidney disease; contrast-induced nephropathy; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Strategies to optimize PCI outcomes in patients with chronic kidney disease.

Similar articles

Cited by

References

    1. Caracciolo A., Mazzone P., Laterra G., Garcia-Ruiz V., Polimeni A., Galasso S., Saporito F., Carerj S., D’Ascenzo F., Marquis-Gravel G., et al. Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. J. Clin. Med. 2019;8:2016. doi: 10.3390/jcm8112016. - DOI - PMC - PubMed
    1. Spertus J.A., Jones P.G., Maron D.J., O’Brien S.M., Reynolds H., Rosenberg Y., Stone G.W., Harrell F.E., Boden W.E., Weintraub W.S., et al. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N. Engl. J. Med. 2020;382:1408–1419. doi: 10.1056/NEJMoa1916370. - DOI - PMC - PubMed
    1. Zijlstra F., Hoorntje J.C., De Boer M.-J., Reiffers S., Miedema K., Ottervanger J.P., Hof A.W.V.T. Long-Term Benefit of Primary Angioplasty as Compared with Thrombolytic Therapy for Acute Myocardial Infarction. N. Engl. J. Med. 2008;341:1413–1419. doi: 10.1056/NEJM199911043411901. - DOI - PubMed
    1. Maron D.J., Hochman J.S., Reynolds H.R., Bangalore S., O’Brien S.M., Boden W.E., Chaitman B.R., Senior R., López-Sendón J., Alexander K.P., et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N. Engl. J. Med. 2020;382:1395–1407. doi: 10.1056/NEJMoa1915922. - DOI - PMC - PubMed
    1. Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.-M., Capodanno D., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceDeveloped by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC) Eur. Heart J. 2021;42:3227–3337. doi: 10.1093/EURHEARTJ/EHAB484. - DOI - PubMed

LinkOut - more resources